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Role of specialized composition of SWI/SNF
complexes in prostate cancer lineage plasticity
Joanna Cyrta et al.#
Advanced prostate cancer initially responds to hormonal treatment, but ultimately becomes
resistant and requires more potent therapies. One mechanism of resistance observed in
around 10–20% of these patients is lineage plasticity, which manifests in a partial or com-
plete small cell or neuroendocrine prostate cancer (NEPC) phenotype. Here, we investigate
the role of the mammalian SWI/SNF (mSWI/SNF) chromatin remodeling complex in NEPC.
Using large patient datasets, patient-derived organoids and cancer cell lines, we identify
mSWI/SNF subunits that are deregulated in NEPC and demonstrate that SMARCA4 (BRG1)
overexpression is associated with aggressive disease. We also show that SWI/SNF com-
plexes interact with different lineage-specific factors in NEPC compared to prostate adeno-
carcinoma. These data point to a role for mSWI/SNF complexes in therapy-related lineage
plasticity, which may also be relevant for other solid tumors.
https://doi.org/10.1038/s41467-020-19328-1 OPEN
#A list of authors and their affiliations appears at the end of the paper.
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Prostate cancer (PCa) is the second most commonly diag-nosed cancer and the fifth cause of cancer-related death inmen worldwide1,2. Although most men are effectively
treated by local therapies (surgery and/or radiotherapy), some
develop metastatic recurrence or present with metastases at initial
diagnosis. The mainstay of treatment for metastatic PCa is
androgen deprivation therapy (ADT), but resistance ultimately
develops with progression to castration-resistant prostate cancer
(CRPC), which typically harbors a “luminal” (adenocarcinoma)
phenotype (CRPC-Adeno) with continued dependence on
androgen receptor (AR) signaling3–5. Improved, more potent
androgen receptor signaling inhibitors (ARSi) have been devel-
oped to treat patients that are not responsive to these therapeutics,
yet acquired resistance to these drugs ultimately develops as well.
In CRPC, indifference to AR signaling may manifest with a dis-
tinct histomorphology and expression of neural-like markers,
leading to neuroendocrine or small cell prostate cancer (CRPC-
NE)5–7. Approximately 10–20% of CRPC cases treated with ARSi
display a neuroendocrine phenotype5,8,9. CRPC-NE no longer
responds to ARSi and carries a dismal prognosis, with a mean
overall survival of 12 months and no specific standard of care
treatment options available10. There is mounting evidence that
CRPC-Adeno can transdifferentiate to an AR-indifferent state
through a mechanism of lineage plasticity under specific genomic
conditions, including but not limited to TP53, RB1, and PTEN
loss4,11–13. Epigenetic regulators, such as EZH2, are also critical in
this process4,12,13. Although the mammalian Switch Sucrose Non-
Fermenting (mSWI/SNF) complex is another major chromatin
regulator well known for its role in physiological processes and
frequently altered in cancer14–16, its putative implication in NEPC
lineage plasticity is unknown.
Mammalian SWI/SNF complexes, also known as Brg/Brahma-
associated factor (BAF) complexes, are a heterogeneous family of
ATP-dependent chromatin remodeling complexes composed of
about 11–15 protein subunits and generally considered as positive
mediators of chromatin accessibility16. These complexes are
evolutionarily conserved in eukaryotes and required for normal
embryonic development16,17. Specialized complex assemblies
with distinct functions have been identified at different stages of
embryogenesis and during tissue maturation18–22. Over 20% of
human malignancies carry a genomic alteration involving at least
one of the SWI/SNF subunit genes14–16, including malignant
rhabdoid tumors23, synovial sarcoma24, small cell carcinoma of
the ovary hypercalcemic type, ovarian clear cell carcinoma,
endometrioid carcinoma, bladder cancer, renal cell carcinoma,
and lung adenocarcinoma, among others14,23,25–27.
To date, SWI/SNF alterations have not been studied in the
context of advanced PCa. In this study, we show that SWI/SNF
composition is altered in the setting of CRPC-NE and that in
contrast to many of the above-cited tumor types, SWI/SNF can
have tumor-promoting functions in PCa. We also provide evi-
dence that SWI/SNF interacts with different lineage-specific
partners throughout PCa transdifferentiation. Collectively, these
findings suggest that specialized SWI/SNF complexes are asso-
ciated with PCa disease progression and may play a role in
therapy resistance.
Results
SWI/SNF subunit expression is altered in CRPC-NE. To define
somatic mutation frequencies of genes encoding SWI/SNF sub-
units across the entire spectrum of PCa, we conducted a com-
prehensive analysis of whole exome sequencing (WES) data from
600 PCa patients representing a wide range of the disease spec-
trum, including 56 CRPC-NE cases (Fig. 1a, Supplementary
Data 1, Supplementary Data 2, Supplementary Data 3). No
recurrent SWI/SNF somatic mutations were observed and there
was a low overall rate of point mutations and insertions/deletions
in those genes (59 samples, 9.8% of all cases) (Fig. 1b). We
observed an increased percentage of loss-of-heterozygosity (LOH)
by hemizygous deletion or copy number neutral LOH (CNNL), in
27 out of 28 genes (significant for 15 genes, proportion test,
alpha= 0.05), when comparing localized hormone treatment-
naïve PCa vs. CRPC-Adeno (Supplementary Fig. 1, Supplemen-
tary Data 1). A similar result was obtained when comparing
localized hormone treatment-naïve PCa and CRPC-NE cases (26
out of 28 genes with higher LOH frequency in CRPC-NE).
Conversely, there were fewer differences when comparing CRPC-
Adeno and CRPC-NE. A significant increase in the fraction of
LOH in CRPC-NE as compared to CRPC-Adeno (proportion
test, alpha= 0.05) was only noted for three genes: BRD7 (51% vs.
30%, respectively, p= 0.005), SMARCD1 (11% vs. 3%, p= 0.04),
and PBRM1 (18% vs. 8%, p= 0.049) (Fig. 1b). However, this was
not accompanied by a decrease in SMARCD1 or PBRM1
expression in CRPC-NE (Supplementary Fig. 2). Expression levels
of BRD7 were significantly lower in CRPC-NE compared to
CRPC-Adeno, but not in CRPC-NE compared to localized PCa.
This is in line with a previous study in which BRD7 loss was
identified as part of a larger heterozygous deletion event enriched
in CRPC-NE and centered around the CYLD gene4. Collectively,
these observations suggest that the increased fractions of LOH
observed in CRPC-NE for BRD7, PBRM1, and SMARCD1 are
unlikely to carry functional significance.
Given the modest differential abundance of genomic lesions,
we next queried the expression levels of SWI/SNF subunits by
examining RNA-seq data of 572 unique PCa patients, including
20 CRPC-NE cases4,5 (Supplementary Data 4). The SMARCA4
ATPase subunit was significantly upregulated, with accompany-
ing downregulation of its mutually exclusive paralogue
SMARCA216,28 in CRPC-NE (n= 20) compared to CRPC-
Adeno (n= 120) with a mean difference of 0.55 (p= 0.015)
(averaged log2(FPKM+ 1)) for SMARCA4 and mean difference
of −0.60 (p= 0.02) for SMARCA2, respectively (Fig. 1c). A
concordant result was observed when comparing SMARCA4/
SMARCA2 expression ratios per patient in CRPC-Adeno (median
ratio= 1.07) and in CRPC-NE (median ratio= 3.06, p= 0.007)
(Supplementary Fig. 3). To validate that these transcriptomic
findings translated into differences in protein expression, we
performed immunohistochemistry (IHC) on patient samples and
confirmed higher SMARCA4 (BRG1) and lower
SMARCA2 (BRM) expression with increasing PCa disease
progression, with highest SMARCA4 expression observed in
CRPC-NE (Fig. 1d and Supplementary Fig. 4).
Importantly, we also identified strong upregulation of neuron-
specific SWI/SNF subunit genes in CRPC-NE: ACTL6B
(BAF53B), DPF1 (BAF45B), and SS18L1 (CREST) (mean log2
[FPKM+ 1] values: 2.79, 1.19, and 3.58, respectively) compared
to CRPC-Adeno (mean 0.24, p= 4.86e−06; mean 0.35, p=
0.0016; and mean 2.76, p= 6.85e−05, respectively) (Fig. 1c).
These subunits are expressed in post-mitotic neurons, serving
instructive functions in neuronal differentiation22. By IHC,
BAF53B, and BAF45B were highly expressed in CRPC-NE, but
absent from benign prostate, localized PCa or CRPC-Adeno
samples (Fig. 1d), demonstrating high specificity for the
neuroendocrine phenotype.
We also noted intra-tumor heterogeneity in the expression of
SWI/SNF subunits, as illustrated by IHC in patient specimens
with a mixed phenotype (combining areas with adenocarcinoma
and neuroendocrine differentiation) (Supplementary Figs. 4 and
5) and in 3D CRPC-NE organoid cultures (Supplementary Fig. 6).
In the latter, we identified distinct cell clusters with high
expression of the neural stem cell factor SOX2, low expression
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Fig. 1 Identification of SWI/SNF subunits deregulated in CRPC-NE. a Summary of the number of patients analyzed by whole exome sequencing (WES)
and RNA-seq for each disease state. b WES results for SWI/SNF genes in 600 samples from unique PCa patients. For each gene, three consecutive bars
represent alteration frequency in localized hormone treatment-naïve PCa, CRPC-Adeno and CRPC-NE, respectively. c RNA-seq analysis of gene expression
levels in 572 unique patient samples from four studies, showing selected genes (ACTL6B: p= 4.86E−06, DPF1: p= 0.0016, SS18L1: p= 6.85E−05,
SMARCA4: p= 0.0015, SMARCA2: p= 0.02) significantly deregulated in CRPC-NE. The core subunit SMARCB1 is shown for comparison. The box plots
represent the median values and the lower and upper interquartile range (IQR); the upper whisker=min(max(x), Q3+ 1.5 × IQR) and lower whisker=max
(min(x), Q1− 1.5 × IQR), and the outliers are plotted as individual points. d Representative immunostainings against BAF47 (SMARCB1), BAF53B (ACTL6B),
BAF45B (DPF1), BRG1 (SMARCA4) and BRM (SMARCA2), and statistical analysis of staining intensity in patient samples. A-benign prostate glands, B-
hormone treatment-naïve localized PCa, C-CRPC-Adeno, D-CRPC-NE. **p < 0.01 (p= 0.0057 for BRG1, p= 0.0012 for BRM), ***p < 0.001 (p= 0.0004 for
BRM) and ****p < 0.0001, ns indicates not significant (two-sided Fisher’s exact test). Scale bars, 50 μm. e Immunoblot showing expression levels of
selected SWI/SNF subunits in PCa cell lines (+++ designates CRPC-NE cell lines). Benign: benign prostatic tissue, PCa: localized hormone treatment-
naïve prostate cancer, CRPC-Adeno: Castration resistant prostate cancer, adenocarcinoma subtype, CRPC-NE: Castration resistant prostate cancer,
neuroendocrine subtype. Source data are provided in the Source Data file.
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of the terminal neuronal marker synaptophysin, and higher
expression of SMARCA4 (BRG1) and SMARCC1 (BAF155) than
in the rest of the cell population (Supplementary Fig. 6). Overall,
these observations suggest a relationship between expression of
specific SWI/SNF subunits and different phenotype states, which
can be seen even in a clonal tumor population.
BAF53B and BAF45B protein expression was confirmed in
CRPC-NE cell lines and organoids (NCI-H660, WCM154, and
WCM15529) (Fig. 1e). BAF53B was also detected, albeit at lower
levels, in two synaptophysin-positive PCa cell lines VCaP and
22Rv1, which bear some degree of transcriptomic similarity to
neuroendocrine PCa cell lines9. BAF45B, on the other hand, was
detected in some CRPC-Adeno cell lines and organoids (DU145,
PC3, and MSKCC-PCA3). Unlike what we observed in patient
samples, we did not observe high SMARCA4 (BRG1) and low
SMARCA2 (BRM) expression in CRPC-NE cell lines, which
could in part be due to marked differences in cell growth rates
among different cell lines (Fig. 1e).
Although in neurons, BAF53B has been characterized as a
mutually exclusive paralog to BAF53A, our data revealed that in
CRPC-NE, BAF53A expression is maintained (Fig. 1e, Supple-
mentary Fig. 7). BAF53B expression in neurons is known to be
mediated by the downregulation of the RE1-Silencing Transcrip-
tion factor (REST), a negative regulator of neuron-specific
genes20. In prostate adenocarcinoma cells, we observed that
short-term REST knock-down led to an increase of BAF53B
(ACTL6B) mRNA and protein levels, but the effect was modest,
while other neuronal genes known to be negatively controlled by
REST (e.g., synaptophysin) were highly upregulated (Supplemen-
tary Fig. 8).
To understand whether high SMARCA4 expression in CRPC-
NE was related to other characteristics of CRPC-NE, such as
acquisition of pluripotent stem cell-like features, and not only to
the expression of terminal neural markers, we performed single-
cell RNA-seq on two CRPC-NE organoids in 3D culture (MSKCC
PCa1 and 16) and confirmed that SMARCA4 expression was
significantly higher in cells with high expression of the
pluripotent stem cell marker SOX2 (Supplementary Fig. 9),
consistent with our IHC findings (Supplementary Fig. 6). Bulk
RNA-seq data from 18 PCa organoids (CRPC-Adeno and CRPC-
NE) (Supplementary Fig. 10) revealed that SMARCA4 expression
was positively correlated with the expression of synaptophysin (a
terminal neuronal marker), but also showed a tendency towards
positive correlation with SOX2; conversely, there was a trend
towards an inverse correlation between SMARCA2 and SOX2
(Pearson correlation analysis). Of note, some organoids (includ-
ing MSKCC PCa1 and PCa16) classified as CRPC-NE based on
their transcriptomic NEPC score4 showed high expression of
SOX2, but low expression of terminal neural markers, such as
synaptophysin (SYP) (Supplementary Fig. 10). These results
suggest that high SMARCA4 expression may be related to
pluripotent stem cell-like features and/or to proliferation at least
in some CRPC-NE, rather than just to the expression of terminal
neuronal markers.
Taken together, the above observations suggest that specialized
SWI/SNF composition varies with PCa lineage plasticity to small
cell or neuroendocrine states.
High SMARCA4 (BRG1) expression is associated with aggres-
sive PCa. We posited that high SMARCA4 expression is asso-
ciated with a more aggressive clinical course. To address this, we
interrogated protein expression of SMARCA4 (BRG1) by IHC in
a cohort of 203 men operated for localized hormone-treatment
naïve PCa (demographics previously described in Spahn et al.30).
High SMARCA4 protein expression in primary PCa was
associated with a significantly shorter overall survival (HR= 2.17
[95% CI: 1.07–4.42], p= 0.028) (Fig. 2a). This relationship
remained significant after adjustment for single covariates that
have known association with PCa outcome (Supplementary
Table 1). Patients with high tumor SMARCA2 (BRM) protein
expression showed a trend towards a better overall survival,
although this relationship did not reach statistical significance.
Taken together, the above findings suggest that high
SMARCA4 expression is associated with more aggressive cases of
PCa.
We next sought to determine the effects of SMARCA4 and
SMARCA2 depletion in PCa cell lines. We performed siRNA-
mediated knock-down of SMARCA4 and SMARCA2 in an
androgen-sensitive (LNCaP) cell line and in a CRPC-Adeno cell
line (22Rv1) and compared global transcriptional alterations
using RNA-seq. As expected, given its posited dominant role,
SMARCA4 depletion demonstrated a stronger effect on the
transcriptome of both cell lines, while SMARCA2 depletion led to
only modest transcriptional alterations (Fig. 2b, Supplementary
Figs. 11 and 12). Among the genes most significantly deregulated
upon SMARCA4 knock-down were several of known significance
in PCa progression, including: upregulation of cell cycle
regulators CDKN1A (p21) and BTG2 (in both LNCaP and
22Rv1 cell lines), downregulation of E2F targets (in both cell
lines), downregulation of EZH2, and downregulation of the
oncogenic long non-coding RNA PCAT-1 (both significant in
LNCaP only)4,31,32 (Fig. 2c–e, Supplementary Fig. 12, Supple-
mentary Data 5, Supplementary Data 6). We also observed a
significant enrichment in gene sets related to EZH2 knock-down,
suggesting that knock-down of SMARCA4 and knock-down of
EZH2 can have partly overlapping effects in PCa cells
(Supplementary Fig. 13). Expression of REST was not altered by
SMARCA4 knock-down (Supplementary Fig. 14).
The observed changes in cell cycle-related pathways led us to
explore the requirement for SMARCA4 and SMARCA2 for PCa
cell growth. Depletion of SMARCA4, but not of SMARCA2,
significantly reduced proliferation of the adenocarcinoma cell line
LNCaP and the LNCaP-derived androgen-independent CRPC-
Adeno cell line C4-2 (Fig. 2f), in line with previous findings33,34.
Knock-down of SMARCA4, but not of SMARCA2, in PCa cells
resulted in a decrease of other SWI/SNF subunits, including
SMARCC1 (BAF155) and ACTL6A (BAF53A), at the protein
level, but not at the transcript level (Supplementary Fig. 15).
Accordingly, both LNCaP and C4-2 cells proved to be highly
sensitive to depletion of BAF155 (SMARCC1) (Supplementary
Fig. 16). Recent work has shown that sensitivity of PCa cells to
SMARCA4 knock-down may be dependent on PTEN loss, via a
mechanism of synthetic lethality33. To expand upon these
findings, we performed knock-down of BAF155 (SMARCC1) in
two PTEN wild-type cell lines, 22Rv1 (CRPC-Adeno) and
WCM154 (CRPC-NE), and observed a significant decrease in
cell growth (Supplementary Fig. 17). This suggests that PTEN-
competent PCa cells can still be sensitive to SWI/SNF disruption,
even though they may be differentially responsive to depletion of
different subunits.
Given that loss of TP53 and/or RB1 has been suggested to
confer a poised pluripotent state required for neuroendocrine
transdifferentiation11,12, we also tested the effect of SMARCA4
knock-down in LNCaP cells having undergone CRISPR-Cas9
mediated knock-out of TP53, RB1, or both genes. The effect of
SMARCA4 knock-down on cell proliferation was not entirely
abrogated by the absence of functional p53 and/or Rb
(Supplementary Fig. 18).
To strengthen the above observations of a putative tumor-
promoting function of SMARCA4 (BRG1) in PCa, we also sought
to study the effects of SMARCA4 overexpression in PCa cells.
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22Rv1 cells were stably transduced with lentiviral vectors
designed to overexpress either SMARCA4 or SMARCA2 or with
a matched empty control vector, and sorted based on the
expression of the fluorescent reporter. Despite strong expression
of the reporters, we did not observe an increase in SMARCA4 or
SMARCA2 at the protein level (Supplementary Fig. 19). However,
after an additional 24 h treatment with the proteasome inhibitor
MG-132, SMARCA4, and SMARCA2 overexpression was readily
detected. These findings hint towards a tight and context-
dependent regulation of catalytic SWI/SNF subunits, as forced
isolated overexpression of a single subunit seems to provoke rapid
degradation of the excess protein. Thus, it is possible that
SMARCA4 overexpression may be necessary, but not sufficient,
to promote an aggressive phenotype in prostate cancer cells.
To understand whether BAF53B and BAF45B—two other
subunits overexpressed in CRPC-NE—potentially regulated
similar gene expression programs as SMARCA4, we performed
shRNA-mediated knock-down of these subunits in the CRPC-NE
organoid line WCM155. Neither BAF53B nor BAF45B knock-
down had an effect on CRPC-NE cell proliferation (Supplemen-
tary Fig. 20) Therefore, it appears that BAF53B and BAF45B
expression may be specific for the CRPC-NE phenotype, but not a
critical mediator of CRPC-NE aggressiveness. Collectively, the
above genomic, transcriptomic, and functional findings support a
tumor-promoting role of SMARCA4-containing mSWI/SNF
complexes in PCa.
Aggressive prostate cancer anti-correlates with SMARCA4
knock-down signature. Based on the association of SMARCA4
expression with poor clinical outcome, and observations that
SMARCA4 knock-down leads to a significant decrease in PCa cell
growth in line with previous studies33,34, we posited that a
SMARCA4 knock-down signature (composed of genes deregu-
lated upon SMARCA4 depletion) would be associated with more
indolent PCa. To address this, we interrogated RNA-seq data of
several large clinical cohorts using a SMARCA4 knock-down
signature derived from the LNCaP PCa cell line (see “Methods”
section) and composed of the top 419 deregulated genes. A high
SMARCA4 knock-down signature score was, indeed, associated
with more indolent disease. In contrast, a low SMARCA4 knock-
down signature score was associated with more aggressive PCa.
As expected, a low SMARCA4 knock-down signature score was
also strongly associated with a CRPC-NE phenotype. We
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examined two CRPC cohorts consisting of 332 patients from the
Stand Up To Cancer-Prostate Cancer Foundation (SU2C-PCF)
trial treated with ARSi5 and 47 patients from the Weill Cornell
Medicine (WCM) cohort4. In the SU2C-PCF cohort, when
considering patients from the highest (top 25%) and lowest
(bottom 25%) quartiles of SMARCA4 knock-down signature
scores (n= 138), low SMARCA4 knock-down signature scores
were significantly more often observed in CRPC-NE cases (n= 16
or 100%) than in CRPC-Adeno cases (n= 57 or 46.7%) (p=
1.77e−05) (Fig. 3a). A similar result was obtained in the WCM
cohort (n= 25): low SMARCA4 knock-down signature scores
were seen in 89% (n= 8) of CRPC-NE cases vs. 31% (n= 5) of
CRPC-Adeno cases (p= 0.011) (Fig. 3b). Furthermore, low
SMARCA4 knock-down signature was associated with a higher
NEPC4 and a lower AR signaling score35 in both cohorts
(Supplementary Table 2). One particularly informative cluster
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was found to show low SMARCA4 knock-down signature scores,
high CRPC-NE scores, and low AR signaling scores (Fig. 3a, red
box). Of note, SMARCA4 mRNA levels were consistent with the
predicted signature score in all analyzed cohorts (Supplementary
Fig. 21).
We next queried if the SMARCA4 knock-down signature was
associated with higher tumor grade, referred to as Gleason score
risk groups in localized PCa36. We first explored 248 patients
from The Cancer Genome Atlas (TCGA) PCa cohort with
localized, hormone treatment-naïve PCa37. Tumors in the highest
Gleason score risk groups (IV and V) more often displayed low
SMARCA4 knock-down signature scores (p < 2.2e−16) (Fig. 3c).
As high tumor grade is associated with risk of metastatic
progression, we decided to validate these findings in other
independent clinical cohorts annotated with clinical survival data.
We calculated SMARCA4 knock-down signature scores for 5239
prospectively collected radical prostatectomy samples from men
with localized PCa and analyzed with the Decipher GRID
transcriptomic platform38. Samples with a low SMARCA4 knock-
down signature (lowest 10%) were significantly enriched (62%)
with high Decipher score, which is a strong surrogate of
metastasis prediction38 (Fig. 3d), compared to 14% in samples
with high SMARCA4 knock-down signature (highest 10%). In
this patient population and consistent with TCGA results, we
observed an association between SMARCA4 knock-down signa-
ture and Gleason score risk categories: signature scores in the
Gleason 9–10 group (mean=−0.13) were significantly lower
compared to the Gleason 6 group (mean= 0.29, p= 1.2 e−56)
(Fig. 3e). We next explored an independent retrospective cohort
from Johns Hopkins Medical Institution (JHMI)39. In the JHMI
cohort, patients with low SMARCA4 knock-down signature
showed a trend towards higher metastasis frequency, the
strongest surrogate for lethal disease progression (Supplementary
Fig. 22). When clustering patients based on the downregulated
genes (Fig. 3f) or on all genes (Supplementary Fig. 23) that make
up the SMARCA4 knock-down signature, overexpression of a
subset of genes involved in cell proliferation was associated with a
cluster of patients enriched with metastatic outcome (Fig. 3f,
box). In summary, these results from large patient cohorts
confirm that the lowest SMARCA4 knock-down signatures are
observed in the most aggressive PCa.
The SWI/SNF complex has distinct lineage-specific interaction
partners in CRPC-NE and in prostate adenocarcinoma cells. To
gain insight into the potential effectors of NEPC-specific epige-
netic regulation, we next sought to identify interactors of mSWI/
SNF in the context of CRPC-NE and prostate adenocarcinoma
cell lines. To this end, we performed co-IP with an antibody
directed against the core SWI/SNF subunit BAF155 (SMARCC1)
at low stringency (see “Methods” section) followed by mass
spectrometry (MS) in NCI-H660 (a CRPC-NE cell line) and in
LNCaP-AR cells (LNCaP cells engineered to overexpress the
androgen receptor40). Proteins that immunoprecipitated with
BAF155 in CRPC-NE cells, but not in adenocarcinoma cells,
(Fig. 4a, b) included BAF53B (ACTL6B) and BAF45B (DPF1)
subunits, as anticipated from results described above, as well as
several factors specific to neural differentiation, such as the
transcription factor NKX2.1 (TTF-1), the microtubule-associated
factor MAP2 and the growth factor VGF. Moreover, we found
several members of the NuRD chromatin remodeling complex,
such as MTA1 and CHD4, to immunoprecipitate with BAF155.
This is in line with previous findings of a potential interaction of
those two chromatin remodeling complexes (Fig. 4a, b)41,42. A
considerable amount of CRPC-NE specific SWI/SNF interactors
were proteins involved in chromatin regulation or DNA repair
(Fig. 4a, b, Supplementary Data 7, Supplementary Data 8).
Conversely, proteins that immunoprecipitated with BAF155 in
adenocarcinoma cells, but not in CRPC-NE, included HOXB13, a
homeobox transcription factor involved in AR signaling43
(Fig. 4b). In line with these findings, genes encoding most of the
above factors were differentially expressed between CRPC-NE
and adenocarcinoma cell lines and organoids (Fig. 4c, Supple-
mentary Fig. 24). Further, we confirmed unique interaction of
factors NKX2.1, CHD4, MTA1, and VGF with BAF155 in NCI-
H660 by immunoblotting, while these interactions were absent in
LNCaP-AR cells (Supplementary Fig. 25a). Interaction of
HOXB13 with BAF155 in LNCaP-AR cells was also confirmed by
immunoblotting (Supplementary Fig. 25b). The co-IP experiment
also showed an enrichment of proteins negatively associated with
REST signaling in NCI-H660 cells, such as HMG20A, a
chromatin-associated protein known to overcome the repressive
effects of REST and induce activation of neuronal genes44. Loss of
expression or altered splicing of REST has been associated with
neural-like lineage plasticity in PCa in multiple studies45–51. An
independent co-IP experiment using an antibody directed against
SMARCA4 followed by MS in NCI-H660 and in LNCaP cells
found similar results for BAF53B, BAF45B, NKX2.1, and
HOXB13 (Supplementary Fig. 26, Supplementary Data 9).
As a proof-of-principle, we compared genome occupancy of
SMARCC1, HOXB13, the active chromatin histone mark
H3K27ac and the inactive chromatin mark H3K27me3 in LNCaP
cells, using published ChIP-seq datasets (Supplementary Fig. 27).
SMARCC1 and HOXB13 colocalized at active chromatin sites
(11,824 sites), while there was almost no overlap between
SMARCC1 and HOXB13 at inactive chromatin sites, thus
suggesting a functional nature of this interaction. Collectively,
the above observations suggest that the set of SWI/SNF
interaction partners in CRPC-NE is quite distinct from the one
in prostatic adenocarcinoma.
Discussion
Whereas neuroendocrine PCa is rarely present at diagnosis in
hormone-treatment naïve PCa patients (de novo neuroendocrine
PCa, <1% of cases)52, recent work supports the hypothesis that
acquisition of a CRPC-NE phenotype in PCa is a more common
mechanism of resistance to ARSi4,5,8,13,53. Based on a recent
review of 440 CRPC patients, CRPC-NE was seen in 11% of
CRPC patients that underwent biopsy5,8,9. There is increasing
evidence that CRPC-NE can directly arise from CRPC-Adeno
cells through lineage plasticity (Supplementary Fig. 28), which is
supported by lineage tracing experiments in a genetically engi-
neered mouse model of PCa with combined Trp53 and Pten
loss54. Moreover, mouse models with Trp53 and Rb1 genomic
loss show lineage plasticity, but epigenetic therapy can re-
sensitize those tumors towards ARSi treatment11. In patient
cohorts, CRPC-NE are characterized by an overexpression of
several epigenetic regulators (such as EZH2) and a specific DNA
methylation profile4,13,29. Overall, these data support the idea that
PCa progression through lineage plasticity is regulated by epi-
genetic changes in a specific genomic context12,55.
Given that mSWI/SNF complexes are major epigenetic reg-
ulators in physiological cell differentiation, we posited that they
may play a role in CRPC-NE lineage plasticity. Specialized
assemblies of the SWI/SNF complex with distinct functions are
observed at different stages of embryonic development and tissue
maturation18,19. The most notable changes in SWI/SNF compo-
sition described to date occur during neuronal differentiation.
Cells committed to the neural lineage initially express a neural
progenitor form of the complex (termed npBAF), which incor-
porates among others the BAF53A, BAF45A/D, and
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SS18 subunits20–22. However, upon differentiation to post-mitotic
neurons, the complex undergoes a switch to the neural variant
and incorporates the respective paralogs of these subunits (i.e.,
BAF53B, BAF45B/C, and SS18L1). This switch is mediated by
repression of BAF53A by micro-RNAs in response to down-
regulation of REST20. In this study, we observed for the first time
the presence of “neuronal” SWI/SNF subunits outside of the
nervous system, characterized by the expression of BAF53B and
BAF45B in CRPC-NE. Although expression of these subunits was
highly specific of CRPC-NE, it remains unclear whether they play
a role in activating neural-like gene programs, or are simply
expressed as a consequence of this process. Additional studies are
warranted to assess the putative utility of BAF53B and BAF45B as
CRPC-NE biomarkers or as predictors of patients at risk of
developing CRPC-NE from CRPC-Adeno while on ARSi. Of
note, expression of the BAF53A paralogue is retained in CRPC-
NE, pointing to potential differences in the way SWI/SNF com-
plexes assemble in post-mitotic neurons and in neuroendocrine
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cancer cells, and to possible co-existence of different forms of the
complex within the same tumor.
This study supports a pleiotropic role for the SWI/SNF chro-
matin remodeling complex in cancer, which may depend on the
genomic and/or the epigenetic context—a paradigm which has
been gaining support both in regards to SWI/SNF and to other
epigenetic regulators56–58. Although the complex has been
described as a tumor suppressor in many cancer types14,23,25,59,
there is increasing evidence for possible tumor-promoting func-
tions of SWI/SNF in other malignancies, including leukemia,
breast, liver and pancreas cancer melanoma, glioblastoma, neu-
roblastoma and synovial sarcoma24,60–65. In PCa, the role of SWI/
SNF has long remained insufficiently characterized. Our study
provides novel evidence that it can have tumor-promoting
functions in PCa, including its most aggressive forms. Based on
prior studies and on the current analysis, mutations in SWI/SNF
genes are very rare in PCa4,5,34,37,66–68 (see Fig. 1b), in contrast to
some other cancers types14,15. From the functional perspective,
inhibition of the SWI/SNF subunits BAF57 (SMARCE1) or
BAF53A (ACTL6A) in PCa cells has been shown to abrogate
androgen-dependent cell proliferation69,70. Similarly, Sandoval
et al. reported that SWI/SNF interacts with ERG in PCa cells
harboring the TMPRSS2:ERG gene fusion and is required to
activate specific gene programs to maintain cell growth71.
Although on the contrary, Prensner et al. had suggested that SWI/
SNF acts as a tumor suppressor in PCa, by demonstrating an
antagonistic relationship between the pro-oncogenic long non-
coding RNA SChLAP1 and the SWI/SNF core subunit BAF4772, a
subsequent study failed to confirm that SChLAP1-SWI/SNF
interaction leads to depletion of SWI/SNF from the genome73.
Most recently, two studies demonstrated that SMARCA4 was
required for growth of prostatic adenocarcinoma cells33,34, as also
confirmed by our results (Fig. 2). Accordingly, localized PCa has
been reported to show higher SMARCA4 and lower SMARCA2
expression than benign prostate tissue33,34,74,75. We confirm
these results and further report an overexpression of SMARCA4
in CRPC and especially in CRPC-NE, in contrast to lower
expression in early PCa. In addition, we show that a low
SMARCA4 knock-down gene signature score is associated with
aggressive PCa, and with a CRPC-NE phenotype.
Recent work by Ding et al. specifically proposed a synthetic
lethal association between PTEN and SMARCA4 in PCa, identi-
fied through a CRISPR-Cas9 screen33. They showed that in vitro,
SMARCA4 knock-down leads to decreased cell proliferation in
PTEN-negative cell lines, and confirmed these findings in a
mouse model. In our study, knock-down of the core SWI/SNF
subunit BAF155 (SMARCC1) and BAF170 (SMARCC2) inhibited
growth of both PTEN-deficient and PTEN-competent PCa ade-
nocarcinoma cells (Supplementary Figs. 16 and 17), and the
PTEN-competent CRPC-NE cell line WCM154 was sensitive to
ablation of BAF155, but not of BAF170. This suggests that even if
PTEN-competent cells are not sensitive to SMARCA4 loss, they
may still be vulnerable to SWI/SNF disruption through depletion
of other critical subunits. Taken together, our and previously
published findings indicate that PCa expands the spectrum of
cancer types in which SWI/SNF can display tumor-promoting
functions.
In addition, we observed that SWI/SNF composition in pros-
tate cancer is not a hard-set feature; instead, specialized forms of
SWI/SNF may assemble in cancer cells depending on their phe-
notype (Fig. 5). There is increasing evidence that de-repression of
“terminal” neuronal genes in PCa cells is not sufficient to model
other critical steps of neuroendocrine lineage plasticity in CRPC-
NE76. As such, the distinct phenotype of CRPC-NE is not limited
to the expression of terminal neuronal markers, but involves
other key characteristics, such as dedifferentiation, AR signaling
indifference, acquisition of stem cell-like features and/or high
proliferation13. In line with this, we show that some patient-
derived PCa organoids that are classified as CRPC-NE using a
transcriptome-based NEPC score4 (Supplementary Fig. 10), do
not all show high expression of terminal neural markers such as
synaptophysin, but instead may highly express factors related to
“stemness” (e.g., SOX2). Based on our observations, it is possible
that specific forms of SWI/SNF are implicated in various above-
mentioned cellular processes, rather than only in the expression
of terminal neuronal markers. One possible hypothesis is that an
equivalent of the embryonic stem cell form of the complex
(esBAF), which is known to exclusively incorporate BRG1
(SMARCA4), BAF53A and BAF155 (SMARCC1) subunits and
not their paralogs18,19, could exist in cancers cells with plur-
ipotent stem cell-like features, and possibly explain the over-
expression and/or the functional requirement for these subunits.
Similarly, neural-like forms of the complex, including BAF53B
and/or BAF45B, could be more specific of cancer cells with a
more terminal neural-like phenotype. Further studies are needed
to determine whether variants of SWI/SNF can co-exist within
the same cell or whether they define distinct tumor sub-popula-
tions, in line with what we have observed in 3D CRPC-NE
organoid cultures (Supplementary Fig. 6).
One of the ways in which SWI/SNF might contribute to CRPC-
NE transdifferentiation is by cooperating with other transcrip-
tional regulators in a context-dependent manner. To this end, we
showed that SWI/SNF interacts with different lineage-specific
proteins in CRPC-NE than in adenocarcinoma cells (Fig. 4b,
Supplementary Fig. 25). In particular, SWI/SNF interacts with the
transcription factor NK2 homeobox 1 (NKX2.1/TTF-1) in CRPC-
NE cells, but not in adenocarcinoma cells (Fig. 4c, Supplementary
Fig. 25). TTF-1 is a master regulator critical for the development
of lung and thyroid, but also of specific parts of the brain77–79 and
is known to be expressed in neuroendocrine neoplasms, including
CRPC-NE76. We also observed SWI/SNF interaction with
Metastasis-associated Protein 1 (MTA1), a member of the
nucleosome-remodeling and deacetylation complex (NuRD),
which is overexpressed in metastatic prostate cancer80 (Fig. 4c).
Conversely, we found HOXB13 to be specifically associated with
SWI/SNF in adenocarcinoma cells, and not in CRPC-NE.
HOXB13 is a homeobox transcription factor involved in prostate
development and displays context-dependent roles in PCa: it can
act as a collaborator or a negative regulator of AR signaling43,81, it
cooperates with the AR-V7 splice variant found in a subset of
CRPC-Adeno82, and germline gain-of-function G84E HOXB13
mutations are associated with increased prostate cancer risk83.
The fact that by ChIP-seq, SWI/SNF colocalizes with HOXB13 at
active chromatin sites in prostatic adenocarcinoma cells, further
supports the hypothesis that interaction between SWI/SNF and
lineage-specific factors in PCa may be meaningful at the
functional level.
In conclusion, this work confirms that SWI/SNF has tumor-
promoting functions in PCa, including the lethal CRPC-NE. Our
findings provide a rationale to further study selected SWI/SNF
subunits as potential therapeutic targets in PCa.
Methods
Genomic analysis. Matched tumor and normal WES data of localized and
advanced prostate cancer from The Cancer Genome Atlas84, SU2C-PCF5 and from
the Weill Cornell Medicine cohort4 were uniformly analyzed for somatic copy
number aberrations (SCNA) with CNVkit85, and for single nucleotide variations
(SNVs) and indels with MuTect286. SNVs and Indels were annotated with variant
effect predictor (VEP)87 and only mutations with HIGH or MODERATE predicted
impact on a transcript or protein (https://www.ensembl.org/info/genome/
variation/prediction/predicted_data.html) were retained. All samples with tumor
ploidy and purity estimated using CLONET88 were retained in the analyses and
processed for allele specific characterization. The integrated dataset includes 299
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unique hormone treatment-naïve prostatic adenocarcinoma (Adeno), 245 castra-
tion resistant prostate adenocarcinoma (CRPC-Adeno), and 56 castration resistant
neuroendocrine prostate carcinoma (CRPC-NE) patients. Two-tailed proportion
test has been used to check enrichment of hemizygous deletion and copy number
neutral loss.
RNA-seq data analysis of human samples. RNA-seq data from 32 normal
prostate samples89,90, 400 localized PCa37,89,90 and 120 CRPC-Adenos and 20
CRPC-NE patients4,5 were utilized for the initial investigation of the SWI-SNF
complex units levels and were processed as follows. Reads (FASTQ files) were
mapped to the human genome reference sequence (hg19/GRC37) using STAR
v2.3.0e91, and the resulting alignment files were converted into Mapped Read
Format (MRF) for gene expression quantification using RSEQtools92 and GEN-
CODE v19 (http://www.gencodegenes.org/releases/19.html) as reference gene
annotation set. A composite model of genes based on the union of all exonic
regions from all gene transcripts was used, resulting in a set of 20,345 protein-
coding genes. Normalized expression levels were estimated as FPKM. After con-
verting the FPKM via log2 (FPKM+ 1), differential expression analysis was per-
formed using Mann-Whitney Wilcoxon test. RNA-seq data of the SU2C-PCF
cohort were downloaded from original study5. NEPC score and AR signaling score
were inferred as previously described5. Gleason scores of the TCGA PCas were
retrieved from the original study37. RNA-seq data and Gleason score from the
TCGA PCa dataset were retrieved from the TCGA data portal using TCGAbiolinks
R package v2.12.293.
Immunohistochemistry. Immunohistochemistry (IHC) was performed on sec-
tions of formalin-fixed paraffin-embedded patient tissue (FFPE) using a Bond III
automated immunostainer and the Bond Polymer Refine detection system (Leica
Microsystems, IL, USA). Slides were de-paraffinized and heat-mediated antigen
retrieval using the Bond Epitope Retrieval 1 solution at pH6 (H1) or Bond Epitope
Retrieval 2 solution at pH9 (H2) or enzyme-mediated antigen retrieval (E1) was
performed. All antibodies, dilutions and conditions used are listed in Supple-
mentary Table 3.
The intensity of nuclear immunostaining for SWI/SNF subunits was evaluated
on tissue micro-arrays (TMAs) and whole slide sections by a pathologist (J.C.)
blinded to additional pathological and clinical data, and was scored as negative
(score 0), weak (score 1), moderate (score 2), or strong (score 3). Association
between disease state and staining intensity (negative/weak vs. moderate/strong)
was examined using the two-tailed Fisher’s exact test.
Analysis of SMARCA4 and SMARCA2 expression in localized PCa vs. clinical
outcome. The patient cohort with localized PCa and available clinical and follow-up
information has been previously described30. IHC for SMARCA4 and SMARCA2
was performed on TMAs constructed from these patients’ prostatectomy specimens.
Staining intensity was scored by a pathologist (J.C.) blinded to the clinical data,
using the digital online TMA scoring tool Scorenado (University of Bern, Swit-
zerland). The Kaplan-Meier method was used to estimate patients’ overall survival.
The association between SMARCA4 and SMARCA2 expression (strong vs. mod-
erate/weak/negative) and overall survival was examined using the log-rank test and
multivariable Cox proportional hazards regression models. Ninety-five percent
confidence intervals were calculated to assess the precision of the obtained hazard
ratios. All p-values were two-sided, and statistical significance was evaluated at the
0.05 alpha level. All analyses were performed in R (3.5.1) for Windows.
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Development of a SMARCA4 knock-down signature. We defined the SMARCA4
knock-down signature by selecting a list of differentially expressed genes between
SMARCA4 siRNA-mediated knock-down and Scrambled control in the LNCaP cell
line with a log fold change of 1.5 and an FDR < 0.01. For each sample, gene
expression data were first normalized by z-score transformation. Then signature
score was calculated as a weighted sum of normalized expression of the genes in the
signature and was finally re-scaled with the 2.5% and 97.5% quantiles equaled −1
and +1, respectively. We defined samples with low SMARCA4 knock-down sig-
nature score as the 25% of cases with the lowest scores, and samples with high
signature score as the 25% of cases with the highest scores.
Validation of SMARCA4 knock-down signature in multiple clinical cohorts.
SMARCA4 knock-down generated signature was applied to two CRPC cohorts
consisting of 332 patients from the Stand Up To Cancer-Prostate Cancer Foun-
dation (SU2C-PCF) trial treated with ARSi (recently published by Abida et al.5)
and 47 patients from the Weil Cornell Medicine (WCM) cohort (published by
Beltran et al.4) and on one cohort of localized, hormone treatment-naïve PCa
consisting of 495 patients from The Cancer Genome Atlas (TCGA).
Results from the signature was then correlated with NEPC score and AR
signaling scores for the SU2C-PCF and the WCM dataset and with Gleason score
for the TCGA dataset.
Decipher GRID analysis. For prospective Decipher GRID and JHMI cohort,
tumor RNA was extracted from FFPE blocks or slides after macrodissection guided
by a histologic review of the tumor lesion by a GU pathologist. RNA extraction and
microarray hybridization were all done in a Clinical Laboratory Improvement
Amendments (CLIA)-certified laboratory facility (GenomeDx Biosciences, San
Diego, CA, USA). Total RNA was amplified and hybridized to Human Exon 1.0 ST
GeneChips (Thermo-Fisher, Carlsbad, CA). All data was normalized using the
Single Channel Array Normalization (SCAN) algorithm94. Decipher scores were
calculated based on the predefined 22-markers38. Patients with high Decipher
(>0.7) were categorized as genomically high risk patients. Mann–Whitney U test
was used to assess score differences across Gleason score groups and
Mann–Kendall trend test was used to test the association between the percentage of
high Decipher scores across deciles of the SMARCA4 knock-down signature.
Kaplan-Meier analysis and Cox proportional hazard model was used to associate
SMARCA4 knock-down signature with time to metastasis in the JHMI cohort.
Cell culture. Commercially available PCa cell lines (RWPE-1, LNCaP, 22Rv1,
VCaP, LAPC4, PC3, DU145, NCI-H660, C4-2) were purchased from ATCC and
maintained according to ATCC protocols. WCM154 and WCM155 CRPC-NE cell
lines have been previously established and were maintained in two-dimensional
monolayer culture according to the previously described protocol29. LNCaP-AR
cells were a kind gift from Dr. Sawyers and Dr. Mu (Memorial Sloan Kettering
Cancer Center) and were cultured as previously described12. MSKCC-PCa3 CRPC-
Adeno cells were a kind gift from Dr. Chen (Memorial Sloan Kettering Cancer
Center) and were maintained identically to WCM154 and WCM155 cells. All cell
lines used and their phenotype are listed in Supplementary Table 4. Cell cultures
were regularly tested for Mycoplasma contamination and confirmed to be negative.
Cell transfection and siRNA-mediated knock-down. ON-TARGET plus siRNA
SMARTpool siRNAs against SMARCA4, SMARCA2, SMARCC1, SMARCC2, and
REST were purchased from Dharmacon. Transfection was performed overnight on
attached cells growing in 6-well plates using the Lipofectamine 3000 reagent
(Thermo Fisher Scientific) to the proportions of 10 μL of 20 μM siRNA per well.
Cells were harvested for protein and RNA extraction 72 h after transfection.
Cell infection, shRNA-mediated knock-down and gene overexpression. The
ACTL6B shRNA and the matching Scrambled shRNA control were a kind gift from
Dr. Cigall Kadoch (Dana Farber Cancer Institute). The vector was pGIPZ and the
target sequence was: sh#1–TGGATCACACCTACAGCAA. The DPF1 shRNA and
the corresponding Scrambled shRNA control were purchased from Genecopoeia.
The vector was psi-LVRU6GP and the target sequences were: sh#1–GAATTAACT
TGTTCTGTGTAT, Scrambled control–GCTTCGCGCCGTAGTCTTA. For
infection, WCM155 cells were collected, resuspended in media containing Poly-
brene (Millipore) and lentiviral particles, and centrifuged at 800 × g at room
temperature for 60 min. Both vectors included a GFP reporter and infection effi-
ciency was confirmed by green fluorescence. Cells were harvested for protein and
RNA extraction 72 h after transfection. Given the short-term nature of the
experiments, selection was not performed. For the SMARCA4 or SMARCA2
overexpression experiment, lentiviral particles were prepared as described above
using the pEZ-Lv203 vector (SMARCA4 gene, eGFP reporter), the pEZLv216
vector (SMARCA2 gene, mCherry reporter) (all vectors Genecopoeia, MD, USA; all
sequence-verified). 22Rv1 cells were infected as described above, cultured and
sorted based on the expression of the fluorescent reporter.
Immunoblotting. Cells were lysed in RIPA buffer with protease and phosphatase
inhibitors (Thermo Fisher Scientific) and total protein concentration was measured
using the DC Protein Assay (Bio-Rad). Protein samples were resolved in SDS-
PAGE, transferred onto a nitrocellulose membrane using the iBlot 2 dry blotting
system (Thermo Fisher Scientific) and incubated overnight at 4 °C with primary
antibodies dissolved in 5% Blotting-Grade Blocker (Bio-Rad). All primary anti-
bodies and dilutions used are listed in Supplementary Table 3. After 3 washes, the
membrane was incubated with secondary antibody conjugated to horseradish
peroxidase for 1 h at room temperature. After 3 washes, signal was visualized by
chemiluminescence using the Luminata Forte substrate (Thermo Fisher Scientific)
and images were acquired with the ChemiDoc™ Touch Imaging System (Bio-Rad,
Hercules, CA). When blotting of a single membrane for different proteins was
necessary, the membrane was stripped using the Restore PLUS Stripping Buffer
(Thermo Fisher Scientific) according to producer’s instructions and the immu-
noblotting process was repeated.
RNA extraction from cells, RNA sequencing and analysis, qPCR. Total RNA
was extracted from cells using the Maxwell 16 LEV simplyRNA Purification Kit
and the Maxwell 16 Instrument. RNA integrity was verified using the Agilent
Bioanalyzer 2100 (Agilent Technologies). cDNA was synthesized from total RNA
using Superscript III (Invitrogen). Library preparation was performed using TruSeq
RNA Library Preparation Kit v2. RNA sequencing was performed on the HiSeq
2500 sequencer to generate 2 × 75 bp paired-end reads.
Sequence reads were aligned using STAR two-pass95 to the human reference
genome GRCh37. Gene counts were quantified using the “GeneCounts” option.
Per-gene counts-per-million (CPM) were computed and log2-transformed adding a
pseudo-count of 1 to avoid transforming 0. Genes with log2-CPM <1 in more than
three samples were removed. Unsupervised clustering was performed using the top
500 most variable genes, Euclidean distance as the distance metric and the Ward
clustering algorithm. When required, the batch effect was removed using the
function removeBatchEffect from the limma R package for data visualization. For
differential expression the batch factor was included in the design matrix.
Differential expression analysis between knock-down cells and control samples
was performed using the edgeR v3.28.1 package96. Normalization was performed
using the “TMM” (weighted trimmed mean) method and differential expression
was assessed using the quasi-likelihood F-test.
Genes with FDR < 0.05 and >2-fold were considered significantly differentially
expressed.
Gene Set Enrichment Analysis (GSEA) was performed using the Preranked
tool97 for C2 (canonical pathways) and H (hallmark gene sets)98. Genes were
ranked based on the T-statistic from the differential expression analysis.
Primer sequences used for qPCR are available in Supplementary Table 5.
Cell growth experiments. Cells were treated with siRNA (3 pmol) against
SMARCA4, SMARCA2, SMARCC1, SMARCC2 or with a scrambled control for
24 h. LNCaP and C4-2 cells were then seeded in Poly-L-Lysine coated 96-well
plates (2000 cells/well) and WCM154 cells were seeded in a collagen-coated 96-well
plates (5000 cells/well). Cell viability was determined after 24, 48, 72, and 96 h with
a Tecan Infinite M200PRO reader using the CellTiter-Glo® Luminescent Cell
Viability Assay according to manufacturer’s directions (Promega). Cell confluence
was determined using the Incucyte S3 instrument and the IncuCyte S3 2018B
software (Essen Bioscience, Germany). Values were calculated as x-fold of cells
transfected with siRNA for 0 h.
Co-immunoprecipitation and mass spectrometry analysis. For the co-
immunoprecipitation (co-IP) using an anti-BAF155 antibody, nuclear fractions of
LNCaP-AR and NCI-H660 cells were isolated using the using the Universal CoIP
Kit (Actif Motif). Chromatin of the nuclear fraction was mechanically sheared
using a Dounce homogenizer. Nuclear membrane and debris were pelleted by
centrifugation and protein concentration of the cleared lysate was determined with
the Pierce BCA Protein Assay Kit (Thermo Fisher Scientific). 2 μg of the anti-
BAF155 antibody (ab172638, Abcam) and 2 μg of rabbit IgG Isotype Control
antibody (026102, Thermo Fisher Scientific) were incubated with 2 mg protein
supernatant overnight at 4 °C with gentle rotation. The following morning, 30 μl of
Protein G Magnetic Beads (Active Motif) were washed twice with 500 μl CoIP
buffer and incubated with Antibody-containing lysate for 1 h at 4 °C with gentle
rotation. Bead-bound SWI/SNF complexes were washed 3 times with CoIP buffer
and twice with a buffer containing 150 mM NaCl, 50 mM Tris-HCL (pH 8) and
Protease and Phosphatase inhibitors. Air-dried and frozen (−20 °C) beads were
subjected to mass spectrometry (MS) analysis. Proteins on the affinity pulldown
beads were re-suspended in 8M Urea/50 mM Tris-HCl pH 8, reduced 30 min at
37 °C with DTT 0.1 M/100 mM Tris-HCl pH 8, alkylated 30 min at 37 °C in the
dark with IAA 0.5 M/100 mM Tris-HCl pH 8, diluted with 4 volumes of 20 mM
Tris-HCl pH 8/2 mM CaCl2 prior to overnight digestion at room temperature with
100 ng sequencing grade trypsin (Promega). Samples were centrifuged and the
magnetic beads trapped by a magnet holder in order to extract the peptides in the
supernatant.
The digests were analyzed by liquid chromatography (LC)-MS/MS (PROXEON
coupled to a QExactive HF mass spectrometer, ThermoFisher Scientific) with three
injections of 5 μl digests. Peptides were trapped on a µPrecolumn C18 PepMap100
(5 μm, 100 Å, 300 μm× 5mm, ThermoFisher Scientific, Reinach, Switzerland) and
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separated by backflush on a C18 column (5 μm, 100 Å, 75 μm× 15 cm, C18) by
applying a 60-min gradient of 5% acetonitrile to 40% in water, 0.1% formic acid, at
a flow rate of 350 nl/min. The Full Scan method was set with resolution at 60,000
with an automatic gain control (AGC) target of 1E06 and maximum ion injection
time of 50 ms. The data-dependent method for precursor ion fragmentation was
applied with the following settings: resolution 15,000, AGC of 1E05, maximum ion
time of 110 ms, mass window 1.6m/z, collision energy 28, under fill ratio 1%,
charge exclusion of unassigned and 1+ ions, and peptide match preferred,
respectively.
MS data was interpreted with MaxQuant (version 1.6.1.0) against a SwissProt
human database (release 2019_02) using the default MaxQuant settings, allowed
mass deviation for precursor ions of 10 ppm for the first search, maximum peptide
mass of 5500 Da, match between runs activated with a matching time window of
0.7 min and the use of non-consecutive fractions for the different pulldowns to
prevent over-fitting. Settings that differed from the default setting included: strict
trypsin cleavage rule allowing for 3 missed cleavages, fixed carbamidomethylation
of cysteines, variable oxidation of methionines and acetylation of protein N-
termini.
Protein intensities are reported as MaxQuant’s Label Free Quantification (LFQ)
values, as well as Top3 values (sum of the intensities of the three most intense
peptides); for the latter, variance stabilization was used for the peptide
normalization, and missing peptide intensities were imputed in the following
manner: if there was at least two evidences in one group of replicates, the missing
value was drawn from a Gaussian distribution of width 0.3 centered at the sample
distribution mean minus 1.8× the sample standard deviation. Imputation at protein
level for both LFQ and Top3 values was performed if there were at least two
measured intensities in at least one group of replicates; missing values in this case
were drawn from a Gaussian distribution of width 0.2 centered at the sample
distribution mean minus 2.5x the sample standard deviation. Differential
expression tests were performed using the moderated t-test empirical Bayes (R
function EBayes from the limma package version 3.40.6) on imputed LFQ and
Top3 protein intensities. The Benjamini and Hochberg method was further applied
to correct for multiple testing. The criterion for statistically significant differential
expression is that the maximum adjusted p-value for large fold changes is 0.05, and
that this maximum decreases asymptotically to 0 as the log2 fold change of 1 is
approached (with a curve parameter of one time the overall standard deviation).
Please see below, the description of the methods for the second Co-IP
(validation experiment) using an anti-BRG1 antibody in LNCaP and NCI-
H660 cells.
CRISPR-Cas9 mediated TP53 and RB1 knock-out. To generate the stable p53 and
RB1 knockout cells, all-in-one CRISPR plasmids with mCherry reporter were
purchased from Genecopoeia (Cat # HCP218175-CG01, HCP216131-CG01). Cells
were transfected with CRISPR plasmids, selected with puromycin and sorted for
mCherry positivity. TP53 gRNA sequences used: TCGACGCTAGGATCTGACTG,
CGTCGAGCCCCCTCTGAGTC, CCATTGTTCAATATCGTCCG. RB1 gRNA
sequences used: CGGTGGCGGCCGTTTTTCGG, CGGTGCCGGGGGTTCCGC
GG, CGGAGGACCTGCCTCTCGTC. Control gRNA sequence: GGCTTCGCGCC
GTAGTCTTA.
Single cell RNA-sequencing (scRNAseq). scRNAseq was performed for two
CRPC-NE organoids in 3D culture: MSK PCa1 and MSK PCa16. Cell counting and
viability tests were conducted using a Moxi Go II Flow Cytometer (Orflo Tech-
nologies) with trypan blue and Propidium Iodide staining. Subsequently, GEM
generation and barcoding, reverse transcription, cDNA amplification and 3′ Gene
Expression library generation steps were all performed according to the Chromium
Single Cell 3′ Reagent Kits v3 user Guide (10× Genomics CG000183 Rev B).
Specifically, 32.0, 11.4, and 40.0 µL of PCa1, PCa8, and PCa16 cell suspension (100,
750, and 200 cells/µL) were used for a targeted cell recovery of 2000, 5000, and
2000 cells, respectively. GEM generation was followed by a GEM-reverse tran-
scription incubation, a clean-up step and 12 cycles of cDNA amplification. The
resulting cDNA was assessed for quantity and quality using fluorometry and
capillary electrophoresis, respectively. The cDNA libraries were pooled and
sequenced paired-end and single indexed on an illumina NovaSeq 6000 sequencer
with a shared NovaSeq 6000 S2 Reagent Kit (100 cycles). The read-set up was as
follows: read 1= 28 cycles, i7 index= 8 cycles, i5= 0 cycles and read 2= 91 cycles.
An average of 300,753,777 reads/library were obtained, equating to an average of
111, 978 reads/cell. All steps were performed at the Next Generation Sequencing
Platform, University of Bern. Data demultiplexing was performed using SEURAT
v. 3.1.5 package (PMID 29608179). Low quality cells and multiplets were excluded
by removing cells with unique feature counts over 5500 or less than 1000. Cells
containing mitochondrial gene counts greater than 25% were also removed. Data
were then scaled to 10,000 and log transformed. Only cells expressing SOX2 and
SMARCA4 genes were included. Boxplots were drawn using GGPLOT2 3.3.0
(https://ggplot2.tidyverse.org) and p-values were calculated using Wilcoxon test.
ChIP-sequencing data analysis. ChIP-seq peaks for SMARCC1 and HOXB13 in
LNCaP cells were downloaded from GEO: GSE110655 and GSE94682, respectively.
ChIP-seq peaks for H3K27ac and H3K27me3 in LNCaP cells were from data
published by Sandoval et al.71. Peak comparison was performed using BEDTOOLS
v2-29.0 (https://bedtools.readthedocs.io/en/latest/#).
Co-immunoprecipitation using the anti-SMARCA4 antibody and mass spec-
trometry analysis. For the second Co-IP (validation experiment) using an anti-
SMARCA4 antibody (results shown in Supplementary Fig. 26 and Supplementary
Data 9), SWI/SNF complexes were isolated from the nuclear fraction of LNCaP
(adenocarcinoma) or NCI-H660 (CRPC-NE) cells, which was prepared using the
Universal CoIP Kit (Active Motif). Briefly, anti-Brg-1 antibodies (H-10, Santa Cruz
Biotechnology) were cross-linked using Dimethyl pimelimidate dihydrochloride
(Sigma-Aldrich) to Protein G conjugated magnetic beads (Bio-Rad). 30 µg of cross-
linked antibodies were incubated with 0.8–1 mg of nuclear lysates overnight. Bead-
bound BAF complexes were washed and eluted using 8 M urea buffer. The
obtained protein complexes were subjected to immunoblotting and MS analysis.
For MS analysis, the eluted proteins were precipitated with trichloroacetic acid
(TCA, 20% w/v), rinsed three times with acetone, and dried at room temperature.
The pellets were re-suspended in 50 µL resuspension buffer (8M urea, 50 mM
ammonium bicarbonate, and 5 mM DTT) and subjected to reduction and
alkylation by adding 15 mM iodoacetamide to each sample for 30 min in the dark
at room temperature, followed by addition of 5 mM DTT to quench the reaction.
Samples were diluted to a final concentration of 2M urea and digested with LysC at
room temperature overnight, and then diluted further to 1 M urea and digested
with Trypsin at 37 °C overnight (for each enzyme a ratio of 1:125 enzyme:protein
was used).
Samples were labeled using reductive dimethylation. Labeling was done while
the peptides were bound to the solid phase C18 resin in self-packed STAGE Tip
micro-columns99. Stage tips were washed with methanol, acetonitrile (ACN) 70%
v/v and formic acid (FA) 1% v/v. Samples were acidified by adding 100% FA to a
final concentration of 2% FA before loading. After sample loading, stage tips were
washed with 1% FA and phosphate/citrate buffer (0.23 M sodium phosphate and
86.4 mM citric acid [pH 5.5]). At this point, the “light” solution (0.4% CH2O and
60 mM NaBH3CN), or “heavy” solution (0.4% CD2O and 60 mM NaBD3CN) was
added twice on each stage tip to label the peptides. A final wash with 1% FA was
performed prior to elution with 70% ACN and 1% FA. Samples were dried under
vacuum, resuspended in 5% FA, and mixed together in equal amounts for
analysis using an Orbitrap Fusion Mass Spectrometer. Peptides were introduced
into the mass spectrometer by nano-electrospray as they eluted off a self-packed
40 cm, 75 μm (ID) reverse-phase column packed with 1.8 μm, 120 Å pore size,
SEPAX C18 resin. Peptides were separated with a gradient of 5–25% buffer B
(99.9% ACN, 0.1% FA) with a flow rate of 350 nl/min for 65 min. For each scan
cycle, one high mass resolution full MS scan was acquired in the Orbitrap mass
analyzer at a resolution of 120 K, AGC value of 500,000, in a m/z scan range of
375–1400, max acquisition time of 100 ms and up to 20 parent ions were chosen
based on their intensity for collision induced dissociation (normalized collision
energy= 35%) and MS/MS fragment ion scans at low mass resolution in the
linear ion trap. Dynamic exclusion was enabled to exclude ions that had already
been selected for MS/MS in the previous 40 s. Ions with a charge of +1 and those
whose charge state could not be assigned were also excluded. All scans were
collected in centroid mode. Two biological replicates for each condition were
processed and analyzed.
MS2 spectra were searched using SEQUEST (version 28 revision 13) against a
composite database containing all Swiss-Prot reviewed human protein sequences
(20,193 target sequences, downloaded from www.uniprot.org March 18, 2016)
and their reversed complement, using the following parameters: a precursor
mass tolerance of ±25 ppm; 1.0 Da product ion mass tolerance; tryptic digestion;
up to two missed cleavages; static modifications of carbamidomethylation on
cysteine (+57.0214) and dimethylation on n-termini and lysines (+28.0313);
dynamic modifications of methionine oxidation (+15.9949) and heavy
dimethylation on N-termini and lysines (+6.03766). Peptide spectral matches
(PSMs) were filtered to 1% FDR using the target-decoy strategy100 combined
with linear discriminant analysis (LDA)101 using several different parameters
including Xcorr, ΔCn’, precursor mass error, observed ion charge state, and
predicted solution charge state. Linear discriminant models were calculated for
each LC-MS/MS run using peptide matches to forward and reversed protein
sequences as positive and negative training data. PSMs within each run were
sorted in descending order by discriminant score and filtered to a 1% FDR as
revealed by the number of decoy sequences remaining in the data set. The data
were further filtered to control protein level FDRs. Peptides were combined and
assembled into proteins. Protein scores were derived from the product of all
LDA peptide probabilities, sorted by rank, and filtered to 1% FDR as described
for peptides. The FDR of the remaining peptides fell dramatically after protein
filtering. The data were further filtered to require a minimum of 8 PSMs per
protein. All peptides were required to have a sum of heavy and light signal-to-
noise (SN) ≧10. Protein ratios were calculated as the log2 ratio of the total SN of
all experimental sample peptide values over that for IgG control sample peptides.
For a small number of the most highly enriched proteins, the control value was
zero (this is the theoretical ideal). In these cases, we imputed a value of one for
ratio calculations. Subsequent visualization and statistical analysis was done with
Perseus and R program102.
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SMARCC1 Co-IP immunoblotting. For the co-immunoprecipitation (co-IP), using
an anti-BAF155 antibody, nuclear fractions of LNCaP-AR and NCI-H660 cells
were isolated using the using the Universal CoIP Kit (Active Motif). Chromatin of
the nuclear fraction was mechanically sheared using a Dounce homogenizer.
Nuclear membrane and debris were pelleted by centrifugation and protein con-
centration of the cleared lysate was determined with the Pierce BCA Protein Assay
Kit (Thermo Fisher Scientific). One microgram of the rabbit anti-BAF155 antibody
(ab172638, Abcam) and 1 μg of rabbit IgG Isotype Control antibody (026102,
Thermo Fisher Scientific) were incubated with 1 mg protein supernatant overnight
at 4 °C with gentle rotation. The following morning, 30 μl of Protein G Magnetic
Beads (Active Motif) were washed twice with 500 μl CoIP buffer and incubated
with Antibody-containing lysate for 2 h at 4 °C with gentle rotation. Bead-bound
SWI/SNF complexes were washed twice with CoIP buffer and twice with a buffer
containing 150 mM NaCl, 50 mM Tris-HCL (pH 8) and Protease and Phosphatase
inhibitors. Washing procedure was executed at 4 °C with gentle rotation. Bead-
bound protein and Input controls are reduced and denatured in 40 μl Laemmli
buffer containing DTT through boiling for 5 min at 95 °C. Magnetic beads are
removed from solution and 20 μl of reduce protein is loaded on an SDS-PAGE gel
with subsequent immunoblotting using iBlot (Life Technologies). Membranes were
blocked in 5% dry-milk solution and then incubated over night with respective
antibodies against targets of interest. Protein signal was detected using HRP-labeled
native anti-rabbit IgG antibody (CST, #5127) and ECL substrate solution (Merck
Millipore) using the Fusion FX.
RNA isolation and qPCR. Cells were first seeded in 10cm-petridish and grown
until they reached a confluency of approx. 90%. The cells were then harvested for
RNA isolation using the RNeasy Mini Kit (Qiagen). Synthesis of complementary
DNAs (cDNAs) using FIREScript RT cDNA Synthesis Kit (Solis BioDyne) and
real-time reverse transcription PCR (RT-PCR) assays using HOT FIREPol Eva-
Green qPCR Mix Plus (Solis BioDyne) were performed using and applying the
manufacturer protocols. Relative mRNA levels of each gene shown were normal-
ized to the expression of the average of housekeeping genes GAPDH and ACTB.
The sequences of the primers for qRT-PCR assays can be found in Supplementary
Table 5.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Data generated during this study have been submitted on the European Genome-
phenome Archive under the accession EGAS00001004177 (https://ega-archive.org/
datasets/EGAD00001005800). The mass spectrometry proteomics data that support the
findings of this study have been deposited to the ProteomeXchange Consortium (http://
proteomecentral.proteomexchange.org) via the PRIDE partner repository with the
dataset identifier PXD016861. Source data are provided with this paper.
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